CoChat

Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin

Porcellati, F., Rossetti, P., Pampanelli, S., Fanelli, C. G., Torlone, E., Scionti, L., Perriello, G., Bolli, G. B. · 2004 · Diabetic Medicine
Cited by 129

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background Glargine is a long‐acting insulin analogue potentially more suitable than NPH insulin in intensive treatment of Type 1 diabetes mellitus (T1 DM), but no study has proven superiority. The aim of this study was to test superiority of glargine on long‐term blood glucose (BG) as well as on responses to hypoglycaemia vs. NPH. Methods One hundred and twenty‐one patients with T1 DM on intensive therapy on four times/day NPH and lispro insulin at each meal, were randomized to either continuation of NPH four times/day (n = 60), or once daily glargine at dinner‐time (n = 61) for 1 year. Lispro insulin at meal‐time was continued in both groups. In 11 patients from each group, responses to stepped hyperinsulinaemic‐hypoglycaemia were measured before and after 1 year's treatment. Results Mean daily BG was lower with glargine [7.6 ± 0.11 mmol/l (137 ± 2 mg/dl)] vs. NPH [8.1 ± 0.22 mmol/l (146 ± 4 mg/dl)] (P < 0.05). HbA 1c at 4 months did not change with NPH, but decreased with glargine (from 7.1 ± 0.1 to 6.7 ± 0.1%), and remained lower than NPH at 12 months (6.6 ± 0.1%, P < 0.05 vs. NPH). Frequency of mild hypoglycaemia [self‐assisted episodes, blood glucose ≤ 4.0 mmol/l (72 mg/dl)] was lower with glargine vs. NPH (7.2 ± 0.5 and 13.2 ± 0.6 episodes/patient‐month, P < 0.05). After 1 year, NPH treatment resulted in no change of responses to hypoglycaemia, whereas with glargine plasma glucose, thresholds and maximal responses of plasma adrenaline and symptoms to hypoglycaemia improved (P < 0.05). Conclusions The simpler glargine regimen decreases the percentage of HbA 1c and frequency of hypoglycaemia and improves responses to hypoglycaemia more than NPH. Thus, glargine appears more suitable than NPH as basal insulin for intensive treatment of T1 DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2004.01323.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 129

Metadata

Authors
Porcellati, F., Rossetti, P., Pampanelli, S., Fanelli, C. G., Torlone, E., Scionti, L., Perriello, G., & Bolli, G. B.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2004-10-20
Volume
21
Issue
11
Pages
1213-1220
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2157105694
Cited by
129
References
5
FWCI
8.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin. https://app.cochat.ai/papers/10.1111/j.1464-5491.2004.01323.x
The paper
Porcellati, F., Rossetti, P., Pampanelli, S., Fanelli, C. G., Torlone, E., Scionti, L., Perriello, G., & Bolli, G. B. (2004). Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2004.01323.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.